SpringWorks [SWTX] vs Blueprint Medicines [BPMC] Detailed Stock Comparison

SpringWorks Therapeutics, Inc.

NASDAQ
Loading...

Blueprint Medicines Corp.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: SpringWorks Therapeutics, Inc. wins in 8 metrics, Blueprint Medicines Corp. wins in 10 metrics, with 0 ties. Blueprint Medicines Corp. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric SpringWorks Therapeutics, Inc. Blueprint Medicines Corp. Better
P/E Ratio (TTM) N/A -120.99 N/A
Price-to-Book Ratio 8.44 24.43 SpringWorks Therapeutics, Inc.
Debt-to-Equity Ratio 1.77 208.50 SpringWorks Therapeutics, Inc.
PEG Ratio -21.96 -137.72 SpringWorks Therapeutics, Inc.
EV/EBITDA -12.49 -53.14 SpringWorks Therapeutics, Inc.
Profit Margin (TTM) -115.60% -27.70% Blueprint Medicines Corp.
Operating Margin (TTM) -164.07% -27.50% Blueprint Medicines Corp.
Return on Equity -51.57% -47.71% Blueprint Medicines Corp.
Return on Assets (TTM) -28.47% -9.75% Blueprint Medicines Corp.
Free Cash Flow (TTM) $-196.30M $-197.22M SpringWorks Therapeutics, Inc.
1-Year Return 27.79% 12.60% SpringWorks Therapeutics, Inc.
Price-to-Sales Ratio (TTM) 16.12 14.89 Blueprint Medicines Corp.
Enterprise Value $3.26B $8.42B Blueprint Medicines Corp.
EV/Revenue Ratio 14.84 14.97 SpringWorks Therapeutics, Inc.
Gross Profit Margin (TTM) 92.81% 98.12% Blueprint Medicines Corp.
Revenue per Share (TTM) $3 $9 Blueprint Medicines Corp.
Earnings per Share (Diluted) $-3.41 $-2.51 Blueprint Medicines Corp.
Beta (Stock Volatility) 0.70 0.83 SpringWorks Therapeutics, Inc.
Short % of Float 10.18% 5.45% Blueprint Medicines Corp.

SpringWorks Therapeutics, Inc. vs Blueprint Medicines Corp. Stock Performance Analysis

Loading Price Chart...

SWTX
BPMC

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
SpringWorks Therapeutics, Inc.0.00%0.04%0.69%27.03%27.03%27.03%
Blueprint Medicines Corp.0.00%0.12%1.05%53.79%61.42%61.42%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
SpringWorks Therapeutics, Inc.27.79%61.20%22.37%107.64%107.64%107.64%
Blueprint Medicines Corp.12.60%149.54%73.38%370.76%598.65%598.65%

Performance & Financial Health Analysis: SpringWorks Therapeutics, Inc. vs Blueprint Medicines Corp.

MetricSWTXBPMC
Market Information
Market Cap i$3.54B$8.37B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i4,023,9575,799,940
90 Day Avg. Volume i4,304,6924,343,357
Last Close$46.99$129.46
52 Week Range$28.21 - $62.00$73.04 - $129.65
% from 52W High-24.21%-0.15%
All-Time High$96.48 (Feb 08, 2021)$129.65 (Jul 16, 2025)
% from All-Time High-51.30%-0.15%
Growth Metrics
Quarterly Revenue Growth1.34%0.56%
Quarterly Earnings Growth1.34%-0.99%
Financial Health
Profit Margin (TTM) i-1.16%-0.28%
Operating Margin (TTM) i-1.64%-0.28%
Return on Equity (TTM) i-0.52%-0.48%
Debt to Equity (MRQ) i1.77208.50
Cash & Liquidity
Book Value per Share (MRQ)$5.57$5.30
Cash per Share (MRQ)$3.82$8.92
Operating Cash Flow (TTM) i$-165,428,000$-145,552,000
Levered Free Cash Flow (TTM) i$-94,371,752$-20,779,750
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: SpringWorks Therapeutics, Inc. vs Blueprint Medicines Corp.

MetricSWTX (Jul 18, 2025)BPMC (Aug 03, 2025)
Price Ratios
P/E Ratio (TTM) iN/A-120.99
Forward P/E i-21.96-137.72
PEG Ratio i-21.96-137.72
Price to Sales (TTM) i16.1214.89
Price to Book (MRQ) i8.4424.43
Market Capitalization
Market Capitalization i$3.54B$8.37B
Enterprise Value i$3.26B$8.42B
Enterprise Value Metrics
Enterprise to Revenue i14.8414.97
Enterprise to EBITDA i-12.49-53.14
Risk & Other Metrics
Beta i0.700.83
Book Value per Share (MRQ) i$5.57$5.30

Financial Statements Comparison: SpringWorks Therapeutics, Inc. vs Blueprint Medicines Corp.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricSWTX (2024)BPMC (2024)
Revenue/Sales i191.59M508.82M
Cost of Goods Sold i12.55M20.16M
COGS % of Revenue i6.6%4.0%
Gross Profit i179.04M488.66M
Gross Margin i93.4%96.0%
Research & Development i200.52M341.43M
Operating Income (EBIT) i-278.13M-212.04M
Operating Margin i-145.2%-41.7%
EBITDA i-274.66M-154.44M
EBITDA Margin i-143.4%-30.4%
Pre-Tax Income i-258.13M-65.86M
Pre-Tax Income % of Revenue i-134.7%-12.9%
Income Tax iN/A1.23M
Income Tax % of Revenue i0.0%0.2%
Net Income (Profit) i-258.13M-67.09M
Profit Margin i-134.7%-13.2%

Balance Sheet & Liquidity Metrics

MetricSWTX (2024)BPMC (2024)
Cash & Equivalents i69.75M102.01M
Total Current Assets i380.47M742.68M
Total Current Assets % of Revenue i198.6%146.0%
Total Current Liabilities i99.99M260.80M
Total Current Liabilities % of Revenue i52.2%51.3%
Long-Term Debt i6.18M411.84M
Long-Term Debt % of Revenue i3.2%80.9%
Total Shareholders Equity i481.10M298.67M
Retained Earnings i-1.15B-2.41B
Retained Earnings % of Revenue i-601.9%-473.1%
Property, Plant & Equipment i11.26M89.90M

Cash Flow Statement Comparison

MetricSWTX (2024)BPMC (2024)
Operating Cash Flow i-215.08M-2.02M
Operating Cash Flow % of Revenue i-112.3%-0.4%
Capital Expenditures iN/A-4.63M
Free Cash Flow i-196.30M-197.22M
FCF Margin i-102.5%-38.8%
Debt Repayment iN/AN/A
Common Stock Repurchase i-8.44MN/A

Short Interest & Institutional Ownership Analysis

MetricSWTXBPMC
Shares Short i6.38M3.13M
Short Ratio i1.460.62
Short % of Float i10.18%5.45%
Shares Outstanding i74.40M63.71M
Float Shares i74.16M60.00M
% Held by Insiders i1.28%0.88%
% Held by Institutions i87.40%109.19%
% Held by Public i11.32%-10.07%

Dividend Analysis & Yield Comparison: SpringWorks Therapeutics, Inc. vs Blueprint Medicines Corp.

MetricSWTXBPMC
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A